Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination

Patent metadata

Field	Value
Publication number	US-11046782-B2
Application number	US-201716089498-A
Country	US
Kind code	B2
Filing date	Mar 30, 2017
Priority date	Mar 30, 2016
Publication date	Jun 29, 2021
Grant date	Jun 29, 2021

Abstract

Isolated or recombinant monoclonal antibodies that bind to GARP are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer. Further provided herein are methods and compositions for treating cancer in an individual comprising administering to the individual an effective amount of an anti-platelet agent and a T cell therapy.

First claim

What is claimed is:

1. A recombinant polypeptide comprising an antibody VH domain comprising CDRs 1-3 of the VH domain of 4d3 (SEQ ID NOs: 1, 2, and 3).

2. A recombinant polypeptide comprising an antibody VL domain comprising CDRs 1-3 of the VL domain of 4d3 (SEQ ID NOs: 5, 6, and 7).

Assignees

• Musc Found For Res Dev

Inventors

• Li Zihai

Classifications

• C07K16/28 Primary

  against receptors, cell surface antigens or cell surface determinants · CPC title

• A61K9/00

  Medicinal preparations characterised by special physical form {(nuclear magnetic resonance contrast preparations or magnetic resonance imaging contrast preparations A61K49/18; preparations containing radioactive substances A61K51/12)} · CPC title

• A61K39/39558

  against tumor tissues, cells, antigens · CPC title

• C07K2317/33

  Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity · CPC title

• C07K16/30

  from tumour cells · CPC title